The market's continued choppiness/consolidating pattern does not mean there aren't growth stocks out there for high-risk investors, and Onyx Pharmaceuticals is one pharmaceutical company that fits the bill.
Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) specializes in small molecule technology, a new, promising method that blocks cancer-causing mechanisms in the human body. In collaboration with Bayer Pharmaceuticals, the company develops and markets compounds that inhibit the function, or modulate the activity of the RAS signaling pathway to treat cancer and other diseases.
Analysts believe ONXX's cancer drug Nexaver as a treatment for advanced kidney cancer could be a big winner, with the company gaining FDA approval for the drug in 2005. ONXX is also testing the drug as a possible treatment for other kinds of cancer (liver, skin, and lung cancer). The Reuters F2007/F2008 EPS consensus estimates for ONXX are -$0.52 to $0.97.
Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) specializes in small molecule technology, a new, promising method that blocks cancer-causing mechanisms in the human body. In collaboration with Bayer Pharmaceuticals, the company develops and markets compounds that inhibit the function, or modulate the activity of the RAS signaling pathway to treat cancer and other diseases.
Analysts believe ONXX's cancer drug Nexaver as a treatment for advanced kidney cancer could be a big winner, with the company gaining FDA approval for the drug in 2005. ONXX is also testing the drug as a possible treatment for other kinds of cancer (liver, skin, and lung cancer). The Reuters F2007/F2008 EPS consensus estimates for ONXX are -$0.52 to $0.97.
Closing Bell: Dubai sends jitters throughout the market (S, BBY)
Heinz looking good after the second quarter?
Why isn't Bank of America updating its shareholders on CEO situation?
